Table 1.

Summary of clinical information of patients

Patient no.	Sex	Stage	Histology	Mutation	WT area (%)	Mutated allele (%)	Hetero‐ geneity group	EGFR amplification	Response	Period between surgery and first gefitinib (months)	Outcome
1	Male	III A	Ad	L858R	0.00	47.9	I	0.9	PR	51	Dead
2	Female	II B	Ad	L858R	0.00	48.0	I	3.4	PR	82	Alive
3	Male	II A	Ad	L858R	0.00	50.4	I	2.8	CR	88	Alive
4	Female	III B	Ad	L858R	0.00	53.2	I	5.9	CR	7	Dead
5	Female	III A	Ad	L858R	0.00	53.9	I	3.0	CR	52	Alive
6	Female	III A	Ad	delE746‐A750	0.00	58.6	I	1.4	CR	88	Dead
7	Female	II B	Ad	delE746‐A750	0.00	58.7	I	3.0	PR	48	Alive
8	Female	I A	Ad	delE746‐A750	0.00	61.5	I	2.7	PR	2	Alive
9	Male	II B	Ad	L858R	0.00	74.2	I	2.9	PR	38	Dead
10	Female	I A	Ad	delE746‐A750	0.00	75.1	I	1.5	PR	18	Alive
11	Female	I A	Ad	delE746‐A750	0.00	81.2	I	1.9	PR	17	Alive (lost from follow up)
12	Female	I B	Ad	delE746‐A750	0.00	82.8	I	2.7	PR	37	Alive
13	Female	I B	Ad	L861Q, G719S	0.00	82.9	I	2.4	PR	35	Alive
14	Female	III A	Ad	delL747‐T751	0.00	84.5	I	4.8	PR	11	Alive (lost from follow up)
15	Female	I B	Ad	delE750‐K758	0.00	93.9	I	2.4	PR	31	Alive
16	Female	II B	Ad	L858R	74.07	24.1	II	2.6	SD	16	Dead
17	Male	III A	Ad	delE746‐A750	6.67	48.3	II	3.3	PR	13	Dead
18	Female	III A	Ad	delE746‐A750	11.54	49.8	II	3.8	CR	39	Alive
19	Female	III B	Ad	E746‐T751 insIP	8.77	54.3	II	2.9	PR	42	Dead
20	Female	II B	Ad	delE746‐A750	8.62	58.1	II	2.3	PR	12	Dead
21	Male	III B	AdSq	delA859‐L883 insV	100.00	NA	II	1.5	PD	73	Dead

Mutated allele (%), ratios of the mutated allele of all areas was calculated, and their median value is shown.

WT area (%), fraction of areas consisting only of the non‐mutant allele. Ad, adenocarcinoma; AdSq, adenosquamous carcinoma; CR, complete response; EGFR, epidermal growth factor receptor; NA, not applicable; PD, progressive disease; PR, partial response; SD, stable disease.